The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Another point I didn't make in my rush was the compound doesn't need to be changed just the rules on how you are allowed to use it. We're selling the rights to use the compound in a way that is stated in the patent.
Yes, RMM I was going to mention that you had said the same but was rushing because a call came in.. It's the most logical and cost-effective way to do it.
Hi Potnak - I said a few weeks ago that there was no logic in putting 1801 into CTA until after the Covid PoC results were out. If the data is good then its fast track for 1801 in both Covid and whatever indication they choose for immune. Furthermore a successful PoC is probably the best advert SAR can get in order to secure a licence. We simply have to wait just a little longer. GLA
People keep talking about funding needed but if TYK2 is all it is cracked up to be, we won't need funding, it will be licenced. Covid\Respiratory has added quite a bit of complexity to any potential deal. At the moment a potential partner can't take respiratory with Immune and they may not want or be able to afford the cost of both. I still think they will split them. I know SOG put an argument across for why that can't currently happen but the indication can be separated in the patents. I'm pretty sure some complex discussions are in motion. The other thing to add is I don't think they will apply for a CTA on 1801 immune until the covid trial has some P1 data. Being the same compound, there might be an argument that the Covid P1 data can be used for Immune P1. Why run two costly P1 trials on the same compound if you can share data between the two. So having said the above. Funding for 1801 immune may not be needed because 1801 covid might be showing promise by then. Needing to fund 1801 immune might mean that 1801 Covid isn't so great. Like I said, it complex but I think the team at SAR have it all in hand and have played a blinder by delaying the 1801 immune CTA.
Ahfam3 true we have £2 million, sure hoping RNS that we are selected for Agile than surely will have funds from the government to promote our much needed technology .
Mazik- the funding issue is sorted we had an investment of £2m+ in the space of 2weeks.
First investment- Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "The Subscription will enable us to continue advancing our lead internal TYK2/JAK1 inhibitor programme, SDC-1801, through its final preclinical studies. We are targeting the completion of these studies in Q3 2021 and are finalising our plans for the initial clinical trials.
"This Subscription, together with any further funds raised and grants awarded to Sareum, will also help us to further explore the potential benefit of SDC-1801 against Covid-19 and TYK2/JAK1 inhibitor SDC-1802 against cancers.
Second investment- Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "We are delighted to have raised these additional funds through this second subscription by the same high net worth individual. These new funds give us greater flexibility to facilitate the planning and execution of our development programmes with our lead internal TYK2/JAK1 inhibitor programme, SDC-1801, which we are advancing through its final preclinical studies. We are targeting the completion of these studies in Q3 2021 and are finalising our plans for the initial clinical trials, which we would expect to commence shortly thereafter, subject to funding.
"These new funds will also help us to further explore the potential benefit of SDC-1801 against Covid-19 and progress the preclinical development of our second TYK2/JAK1 inhibitor SDC-1802 against cancers.
Sareum is currently investigating SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in a preclinical Covid-19 research programme. The programme, which commenced in December 2020 with grant funding from the UK government, is expected to take approximately six months to complete and aims to investigate the effects of SDC-1801 on cytokine signalling after human cells are infected with SARS-CoV-2, to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease. The Company is also investigating whether treatment with SDC-1801 in disease models can re-establish protection against bacterial pneumonia following SARS-CoV-2 infection.
The Company has previously stated it would require additional funding to advance SDC-1801 into clinical trials depending both on positive results from its ongoing Covid-19 research programme and on the successful outcome of the Company's broader preclinical development programme with SDC-1801. The Company believes that, should the current preclinical work programme be successful and indicate that SDC-1801 is a potential treatment for severe-phase Covid-19, the Company may be eligible for an AGILE grant. Further update is imminent with rerate its SP to more like 20p in the making of a big setup like Halozyme in development and commercial milestones per target, subject to achievement of specified development and commercial milestones, including certain specified sales milestones. Halozyme will also be entitled to receive mid-single digit royalties on sales of commercialised medicines using the technology.
111 for the believers just in'' SP looking good 3% up ATM